NeuroOne Medical Technologies Corporation (OTC: NMTC) has entered into a development and distribution deal that may be the first of more to come with Zimmer. In July, the company finalized an agreement with Zimmer Biomet (NYSE: ZBH) to market its Evo™ Cortical Electrode (Evo), the company’s first FDA 510(k)-cleared product. The Evo Cortical Electrode is an innovative product indicated for recording, monitoring, and stimulating brain tissue for up to 30 days. Utilizing proprietary automated manufacturing processes, the thin-film lightweight design offers high-resolution capabilities, reduced immunological response—as demonstrated in pre-clinical studies—and the potential to be placed in a minimally invasive manner. NeuroOne has developed its products in collaboration with the University of Wisconsin-Madison’s Alumni Research Foundation and the Mayo Foundation for Medical Education and Research.
The terms of the deal give Zimmer Biomet the exclusive global right and license to distribute NeuroOne’s strip and grid electrodes and electrode cable assembly products and the exclusive right and license to distribute certain depth electrodes developed by NeuroOne. In connection with the agreement, Zimmer Biomet made a $2 million upfront payment to NeuroOne. Additionally, in order to maintain its exclusive rights to distribute the depth electrodes, Zimmer Biomet must make an additional payment to NeuroOne according to the terms of the agreement.
That value can be recognized on at least two levels. On top of adding cash to its balance sheet, NeuroOne has established a working partnership with Zimmer. The deal with Zimmer is expected to free up NeuroOne’s development team to focus on accelerating the development of new therapeutic technologies as well as provide additional capital to build the company infrastructure.
NeuroOne received its first FDA 510(k) clearance for its Evo™ Cortical Electrode product family in November of 2019. NeuroOne is also in late-stage development of a second hi-definition thin-film electrode product, its Evo™ sEEG Depth Electrode, a device that records brain activity placed through a minimally invasive procedure. Other products in pre-development and conceptual stages include an ablation electrode, a spinal cord stimulation electrode, and a deep brain stimulation electrode.
The most attractive feature of these products is that they each have the potential to deliver a best-in-class option to treatment professionals.
Video Link: https://www.youtube.com/embed/mtUw5KdqYO0
Balance Sheet Strengthened And Prepared To Grow In 2020
As NeuroOne faces the second half of 2020, it expects to be well-funded to advance through development and commercialization processes, as the company recently benefited from a more than $5 million private capital raise in addition to the upfront payment from Zimmer. That cash is expected to put the company in strong financial shape to direct its strategy of near term growth through product development and commercialization.
Great products often lead to great results, and NeuroOne expects it can deliver on both.
To find out more visit https://get.ceo3in60.com/neuroone/
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures